Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
HUTCHMED (China) ( (HK:0013) ) has shared an announcement.
HUTCHMED (China) Limited has confirmed that as of December 31, 2025, its issued share capital comprises 872,327,620 ordinary shares, each carrying one voting right, with no shares held in treasury. The company noted that this total will serve as the reference figure for investors calculating disclosure thresholds under UK transparency rules, and it is equivalent to the same number of depositary interests on AIM or 174,465,524 American depositary shares on Nasdaq, clarifying the capital structure for shareholders across its multiple listings.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. It advances drug candidates from in-house discovery to global markets, with three medicines already marketed in China and its first product also approved in major regions including the US, Europe and Japan.
Average Trading Volume: 4,874,793
Technical Sentiment Signal: Sell
Current Market Cap: HK$17.91B
For a thorough assessment of 0013 stock, go to TipRanks’ Stock Analysis page.